期刊文献+

不同血管活性药物对感染性休克患者动脉血乳酸及乳酸清除率的影响 被引量:9

下载PDF
导出
摘要 目的探讨不同血管活性药物对感染性休克患者动脉血乳酸及乳酸清除率的影响。方法选取感染性休克患者54例,按患者使用血管活性药物不同,分为A、B、C组,每组18例。所有患者均进行充分液体复苏,A组给予多巴胺1~15μg.kg-1.min-1;B组给予去甲肾上腺素0.05~0.50μg.kg-1.min-1;C组给予去甲肾上腺素+多巴酚丁胺1~15μg.kg-1.min-1。比较用药后动脉血乳酸及乳酸清除率变化。结果 B组和C组动脉血乳酸浓度低于A组,乳酸清除率高于A组(P<0.01),24h后平均动脉压较A组明显升高(P<0.05)。结论感染性休克患者应用去甲肾上腺素或去甲肾上腺素+多巴酚丁胺在降低动脉血乳酸浓度、加快乳酸清除率、提高平均动脉压效果、改善组织缺血低氧明显优于多巴胺。
出处 《医药导报》 CAS 2011年第1期66-68,共3页 Herald of Medicine
  • 相关文献

参考文献6

  • 1ANGUS D C, LINDE-ZWIRBLE W T, LIDICKER J, et al. Epidemiology of severe sepsis in the United States:analysis of incidence, outcome, and associated costs of care [ J ]. Crit Care Med,2001,29( 9 ) :1303-1310.
  • 2邱海波.感染性休克血管活性药物应用的再评价[J].中华医学杂志,2002,82(14):1005-1006. 被引量:26
  • 3DEQORICIJA V, SHAMLA M, LEQAC A,et al. Survival analysis of 314 episodes of sepsis in medical care unit in university hospital:impact of intensive care unit perfomance and antimicrobial therapy [ J ]. Croat Med,2006,47 ( 3 ) :385- 397.
  • 4JOYNT G M,LIPMAN J. Gastric intramucosal pH and blood lactate in severe sepsis [ J ]. Anaesthesia, 1997,52 ( 7 ) ,726- 732.
  • 5HUSAIN F A, MARTIN M J, MULLENIX P S,et al. Serum lactate and base deficit as predictors of mortaity and morbidity[ J ]. Am J Surg,2003,18 (5) :485-491.
  • 6RUODONEN E,TAKALA J, KARIA ,et al. Regional blood flow and oxygen transport in septic shock [ J ]. Crit Care Meal,1993,21 ( 11 ) :1296-1303.

共引文献25

同被引文献63

  • 1严静.成人严重感染与感染性休克血流动力学监测与支持指南(2006)[J].中国实用外科杂志,2007,27(1):7-13. 被引量:132
  • 2邱海波.严重感染和感染性休克的治疗进展[J].中华肝胆外科杂志,2007,13(1):4-6. 被引量:9
  • 3张琳,周炳凤,章车明.大剂量去甲肾上腺素在重度休克中的应用[J].中国基层医药,2007,14(6):969-970. 被引量:2
  • 4Bracco D, Dubois MJ. Hemodynamic support in septic shock: is restoring a normal blood pressure the right target [ J ]. Crit Care Med, 2005,33 (9) :2113-2115.
  • 5Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepator- enal syndrome parallels increase in mean arterial pressure: a pooled anal- ysis of clinical trials [ J ]. Am J Kidney Dis, 2011,58 (6) :928-938.
  • 6Maybauer MO, Maybauer DM. Vasopressin analogues and V1 a receptor agonists in septic shock[J]. Inflamm Res,2011,60(5) :425-427.
  • 7Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cir- rhosis and type 1 hepatorenal syndrome: a retrospective muhicenter study [ J ]. Gastroenterology,2002,122 (4) :923-930.
  • 8Dellinger RP,Levy MM,Carlet JM,et al. Surviving Sepsis Campaign:International guidelines for management of se- vere sepsis and septic shock:2008[J].Intensive care medi- cine,2008,34( 1 ) : 17-60.
  • 9Levy MM,Fink MP, Marshall JC,et al. SCCM/ESICM/AC- CP/ATS/SIS.2001SCCM/ESICM/ACCP/ATS/SIS Internation- al Sepsis Definitions Conference [J ].critical care medicine, 2003,31(4): 1250-1256.
  • 10Rivers E,Nguyen B,Havstad S,et al.Early goal-directed therapy in the treatment of severe sepsis and septic shock [ J ].The New England journal of medicine, 2001,345 ( 19 ) : 1368-1377.

引证文献9

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部